Connect your AI

Bausch + Lomb BLCO 2030

2030 at other companies

The Cooper Companies, Inc.COO

——

Tarsus Pharmaceuticals, Inc.TARS

——

SolventumSOLV

——

PBH

Prestige Consumer HealthcarePBH

——

Mirum Pharmaceuticals, Inc.MIRM

——

ViatrisVTRS

——

Other financials

Income statement

Revenue$1.2B+9.4%

Operating income$33.0M+140%

Net income-$71.0M+66.5%

EPS (diluted)-$0.20+66.7%

Balance sheet

Cash & equivalents$279.0M+29.8%

Total debt$5.0B+4.3%

Total equity$6.4B+0.3%

Total assets$13.8B+2.6%

Cash flow

Operating cash flow$32.0M+228%

CapEx$100.0M-9.1%

Free cash flow-$68.0M+49.6%

Valuation

Market cap$5.43B+10.2%

Profitability

Operating margin4.4%+2.9pp

Net margin-4.2%-1.3pp

FCF margin-3.4%0.0pp

Returns & leverage

Return on equity-3.4%-0.9pp

Debt / equity0.8×0.0×

Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's 2030.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bausch + Lomb's 2030?: Bausch + Lomb (BLCO) reported 2030 of $216M in Q1 2026.
How has Bausch + Lomb's 2030 changed year-over-year?: Bausch + Lomb's 2030 increased by 0.9% year-over-year, from $214M to $216M.